Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials

MLA

Christina Ciaccio, et al. “Participant Characteristics and Safety Outcomes of Peanut Oral Immunotherapy in the RAMSES and ARC011 Trials.” Annals of Allergy, Asthma & Immunology, vol. 129, Dec. 2022, p. 758–768.e4. EBSCOhost, https://doi.org/10.1016/j.anai.2022.07.033.

APA

Christina Ciaccio, Alan B. Goldsobel, Aikaterini Anagnostou, Kirsten Beyer, Thomas B. Casale, Antoine Deschildre, Montserrat Fernández-Rivas, Jonathan O’B. Hourihane, Marta Krawiec, Jay Lieberman, Amy M. Scurlock, Brian P. Vickery, Alex Smith, Stephen A. Tilles, Daniel C. Adelman, Kari R. Brown, Amal H. Assa’ad, David I. Bernstein, J. Andrew Bird, … William H. Yang. (2022). Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. Annals of Allergy, Asthma & Immunology, 129, 758–768.e4. https://doi.org/10.1016/j.anai.2022.07.033

Chicago

Christina Ciaccio, Alan B. Goldsobel, Aikaterini Anagnostou, Kirsten Beyer, Thomas B. Casale, Antoine Deschildre, Montserrat Fernández-Rivas, et al. 2022. “Participant Characteristics and Safety Outcomes of Peanut Oral Immunotherapy in the RAMSES and ARC011 Trials.” Annals of Allergy, Asthma & Immunology 129 (December): 758–768.e4. doi:10.1016/j.anai.2022.07.033.